RuiYi Inc. Raises $15 Million for US-China mAb Development

RuiYi Inc., which is headquartered in San Diego and has operations in Shanghai, raised $15 million in a Series B round from existing investors. The new capital will facilitate development of RuiYi's lead molecule, RYI-008, a novel anti-IL-6 monoclonal antibody (mAb) targeting inflammation and cancer, along with development of other new therapeutic mAbs targeting GPCRs, including a first-in-class mAb to cannabinoid receptor 1 (CB-1). More details.... Share this with colleagues: // //